Trials / Completed
CompletedNCT05043506
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies Assessed in a Real-World Non-Interventional Study (EUCHARIS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,939 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective observational analysis of de-identified data from a multinational medical record review to describe patient characteristics, treatment patterns, and effectiveness of palbociclib + AI as first-line therapy among adult patients with HR+/HER2- advanced breast cancer (ABC) in Europe
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palbociclib + aromatase inhibitor | Palbociclib + an aromatase inhibitor therapy |
| DRUG | Aromatase inhibitor | Aromatase inhibitor monotherapy |
Timeline
- Start date
- 2022-02-08
- Primary completion
- 2023-11-02
- Completion
- 2023-11-02
- First posted
- 2021-09-14
- Last updated
- 2024-03-27
Locations
64 sites across 7 countries: Austria, Belgium, Germany, Spain, Sweden, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05043506. Inclusion in this directory is not an endorsement.